Improving immune response in triple negative breast cancer using a combination of therapies
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
This study is testing a new combination treatment for people with triple negative breast cancer to see if it can help boost the immune system's ability to fight the cancer, while also checking how safe and effective it is for patients.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project ID | NIH-10909892 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for patients with triple negative breast cancer (TNBC) by combining a CD40 agonist, Flt3 ligand, and anthracycline chemotherapy. The goal is to enhance the activation of antigen presenting cells (APCs), which play a crucial role in initiating the body's immune response against tumors. By assessing the safety and effectiveness of this triplet therapy in a clinical trial, researchers aim to identify biomarkers that can predict patient responses. Patients will receive this combination treatment while their tissue samples are monitored to understand how the therapy works and its potential benefits.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic triple negative breast cancer who have not responded well to standard treatments.
Not a fit: Patients with non-metastatic breast cancer or those with other types of breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and better outcomes for patients with triple negative breast cancer.
How similar studies have performed: Other research has shown promising results with similar approaches that enhance immune responses in various cancers, suggesting potential for success in this area as well.
Where this research is happening
Dallas, United States
- Ut Southwestern Medical Center — Dallas, United States (Active)
Researchers
- Principal investigator: Reddy, Sangeetha Meda — Ut Southwestern Medical Center
- Study coordinator: Reddy, Sangeetha Meda
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.